Toggle navigation
PDFSEARCH.IO
Document Search Engine - browse more than 18 million documents
Sign up
Sign in
Back to Results
First Page
Meta Content
View Document Preview and Link
XOLAIR® CRITERIA Pharmacology: Omalizumab inhibits the binding of IgE to the high-affinity IgE receptor (FceRI) on the surface of mast cells and basophils. Reduction in surface-bound IgE on FceRI-bearing cells limits th
Add to Reading List
Document Date: 2014-09-11 16:49:00
Open Document
File Size: 24,36 KB
Share Result on Facebook
City
South San Francisco /
/
Company
Genentech /
/
Facility
University of Michigan Medical Center /
/
MedicalCondition
Allergic Asthma /
severe persistent asthma /
peanut allergy /
asthma /
/
Organization
Therapeutic Committee Commissioner Pharmacy & Therapeutic Committee Commissioner DUR Board /
American Academy of Allergy /
Asthma /
and Immunology /
University of Michigan Medical Center /
/
Person
Robert B. Jr /
Philip Marcus /
/
Position
Commissioner /
/
Product
Theophylline /
XOLAIR /
/
ProvinceOrState
California /
Michigan /
/
URL
www.aaaai.org /
/
SocialTag
Immune system
Immunology
Allergology
Monoclonal antibodies
Granulocytes
Omalizumab
Immunoglobulin E
Allergy
FcεRI
Biology
XOLAIR® CRITERIA Pharmacology: Omalizumab inhibits the binding of IgE to the high-affinity IgE receptor (FceRI) on the surface of mast cells and basophils. Reduction in surface-bound IgE on FceRI-bearing cells limits th